title: Replacing statins with PCSK9-inhibitors and delaying treatment until 18 years of age in patients with familial hypercholesterolaemia is not a good idea.
authors.affiliation: Lipid Clinic, Oslo University Hospital, Forskningsveien 2 B, Postboks 4950 Nydalen, Oslo 0424, Norway glangsle@ous-hf.no gilang@online.no.
authors.forename: Gisle
authors.initials: G
authors.lastname: Langslet
mesh_terms: D000924:Anticholesteremic Agents; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D006938:Hyperlipoproteinemia Type II; D000071449:Proprotein Convertase 9
chemical_list: D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9